Help the Future of Cancer Treatment

Volunteering for a clinical trial is a contribution to the future of medicine that only you can make.

SJiMB21: Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children with Newly Diagnosed Medulloblastoma

Primary Investigator
Upadhyaya, Santhosh
Status
OPEN TO ACCRUAL
Phase
II
NCT Number
NCT05535166
UM Number
2023.020
Age Group
Children
Management Group
CTSU - Michigan
Oncology Group
Childhood Cancers
ID (Protocol)
43035
Secondary Protocol No
HUM00230699
Scope
Unspecified
Sponsor Type
Institutional
Disease Site
Brain and Nervous System
Summary
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.

Eligibility: